Published in Endocrinology on August 12, 2015
Antiproliferative activities of Amaryllidaceae alkaloids from Lycoris radiata targeting DNA topoisomerase I. Sci Rep (2016) 0.79
Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. Oncotarget (2016) 0.75
Strategic Chemotherapy for Pheochromocytoma? Endocrinology (2015) 0.75
Screening for Natural Inhibitors of Topoisomerases I from Rhamnus davurica by Affinity Ultrafiltration and High-Performance Liquid Chromatography-Mass Spectrometry. Front Plant Sci (2017) 0.75
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer (2002) 5.63
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci (2012) 4.96
Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem (2000) 4.36
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res (2002) 2.97
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol (2008) 2.57
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science (1989) 2.11
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One (2009) 1.75
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer (2013) 1.63
An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res (2012) 1.62
Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol (2001) 1.55
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer (2008) 1.54
Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab (2007) 1.51
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents (2003) 1.31
Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab (2006) 1.31
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol (2010) 1.26
Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis (2009) 1.26
Treatment of malignant pheochromocytoma. Horm Metab Res (2009) 1.25
Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer (2004) 1.21
Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol (1995) 1.20
Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep (2013) 1.19
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res (2012) 1.06
Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol (2012) 1.05
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet (2013) 1.05
Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res (2013) 0.99
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst (2013) 0.98
Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology (2013) 0.92
Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol (2014) 0.92
Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Lett (2011) 0.92
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med (2012) 0.92
Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes (2013) 0.92
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One (2012) 0.89
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol (2009) 0.88
An update on the genetics of pheochromocytoma. J Hum Hypertens (2012) 0.87
Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies? Endocr Pathol (2012) 0.87
Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med (2011) 0.87
TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. J Cancer Sci Ther (2014) 0.81
Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines. PLoS One (2014) 0.78
A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2014) 0.77